Lantheus to buy radiopharma player Evergreen Theragnostics for $250M upfront
In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and diagnostics company Evergreen Theragnostics, which could also receive up to...
View ArticleAkero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug
Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the same ...
View ArticleBiopharma execs split on RFK Jr. before confirmation hearing
Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he may run the nation's health department. Capitol Hill's questioning could...
View ArticleLeap Therapeutics treks toward pivotal study in colorectal cancer, drops...
Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s shares...
View ArticleWhat we know — and don’t know — about insurance denial rates
One insurance metric that we don’t often see showing up on earnings calls: the rate at which health plans issue denials. In the wake of UnitedHealthcare CEO Brian Thompson’s murder last month, a lot of...
View ArticleSemaglutide, tirzepatide compounder hit with FDA warning letter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and tirzepatide production. The FDA uncovered several issues at ProRx’s facility in...
View ArticleOne February FDA adcomm meeting is delayed, another canceled
An FDA advisory committee meeting for a kidney drug has been canceled, and another meeting to discuss opioids has been delayed, amid ongoing confusion and disruption in several US government health...
View ArticleOzempic label expanded to include reduced risk of worsening kidney disease
The FDA on Tuesday broadened the label of Novo Nordisk's blockbuster diabetes drug Ozempic. The GLP-1 injectable can now also be marketed for the reduction in risk of worsening kidney disease ...
View ArticleAstraZeneca, Daiichi Sankyo bring Enhertu to HER2-ultralow setting
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein. The blockbuster drug has been...
View ArticleLilly cuts mid-stage heart failure and chronic kidney drug
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News. The drug, an under-the-skin...
View ArticleJudge allows Aurion Biotech's path to IPO despite Alcon objections
A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow the cell therapy startup to go ahead with its public offering. The judge' ...
View ArticleUpdated: Zentalis lays off 40% of staff, whittles down indications for WEE1...
Zentalis Pharmaceuticals is axing about 40% of its staff and refocusing its only pipeline candidate on a smaller group of ovarian cancer patients. The San Diego-based biotech had 168 full-time...
View ArticleKennedy hearing updates: Trump HHS nominee faces Senate
Through a contentious three-and-a-half-hour hearing, Robert F. Kennedy Jr. emerged relatively unscathed as the Senate considers his nomination for HHS secretary. Democratic senators grilled Kennedy...
View ArticleTrump administration makes first comments on how it will run IRA drug...
The Trump administration said on Wednesday it will consider "opportunities to bring greater transparency” to the Medicare drug price negotiation process under the Inflation Reduction Act. With the...
View ArticleCurie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab
Plus, news about Cullinan Therapeutics, Regulus and Imvax: Curie.Bio’s new $340M fund: The investment firm and biotech startup incubator disclosed the second seed fund on Wednesday. Curie.Bio generally...
View ArticleLonza looks to buy facilities and tech to boost service offerings
Lonza said Wednesday morning it is on the hunt for deals to increase its capacity and technology offerings, which comes after its revenues took a small hit last year and it recently revealed plans to ...
View Article8VC, a tech and life sciences VC firm behind Altos Labs, eyes $1B fund
8VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is aiming to raise about $1 billion for its sixth fund, according to a new SEC ...
View ArticleTeva CEO says Austedo can grow 'way beyond' impact of IRA
Teva CEO Richard Francis said he expects sales growth to continue for the company’s top-selling drug Austedo, even after it becomes subject to new prices negotiated under the Inflation Reduction Act....
View Article